← Leaderboards
Claudia R Morris
Children'S Hospital &Res Ctr At Oakland
$13,915,275
Attributed
$13,915,275
Total exposure
15
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,117,687 · 13
FDA$2,797,588 · 2
By mechanism
UH3$6,920,555 · 1
R01$2,797,588 · 2
UG3$1,537,648 · 1
K24$1,329,307 · 1
K23$647,435 · 1
R34$602,253 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Arginine”
- Paul R Thompson · University Of South Carolina At Columbia$13,563,580
- Michael J. Detke · Embera Neurotherapeutics, Inc.$12,591,952
- John R Guy · University Of Florida$12,441,515
- Elliot Israel · Brigham And Women'S Hospital$11,585,579
- Charles David Allis · University Of Virginia Charlottesville$11,522,091
- Denisa D Wagner · Boston Children'S Hospital$10,614,511
Research focus
ArginineSickle Cell AnemiaNitric OxideClinical ResearchHuman SubjectVasodilator AgentsAccident And Emergency DepartmentChildRandomizedPlacebosResolutionDeath RateHydration StatusChildhoodHospitalizationAcute PainAbsence Of Pain SensationClinical PracticePainLength Of StaySafetyDouble-Blind Placebo Controlled TrialAmino AcidsEmergency Department Visit
Grant awards (48)
1/2 Sickel Cell Disease Treatment with Arginine Therapy (STArT Trial)$1,136,987
UH3 · FY2025 · HL · contact PI
Patient-Oriented Research in Arginine Deficiency Syndromes$142,159
K24 · FY2025 · AT · contact PI
1/2 Sickel Cell Disease Treatment with Arginine Therapy (STArT Trial)$1,362,205
UH3 · FY2024 · HL · contact PI
Patient-Oriented Research in Arginine Deficiency Syndromes$143,384
K24 · FY2024 · AT · contact PI
1/2 Sickel Cell Disease Treatment with Arginine Therapy (STArT Trial)$1,380,591
UH3 · FY2023 · HL · contact PI
Patient-Oriented Research in Arginine Deficiency Syndromes$144,573
K24 · FY2023 · AT · contact PI
1/2 Sickel Cell Disease Treatment with Arginine Therapy (STArT Trial)$1,497,960
UH3 · FY2022 · HL · contact PI
Patient-Oriented Research in Arginine Deficiency Syndromes$177,832
K24 · FY2022 · AT · contact PI
1/2 Sickel Cell Disease Treatment with Arginine Therapy (STArT Trial)$1,542,812
UH3 · FY2021 · HL · contact PI
Patient-Oriented Research in Arginine Deficiency Syndromes$178,791
K24 · FY2021 · AT · contact PI
1/2 Sickel Cell Disease Treatment with Arginine Therapy (STArT Trial)$1,537,648
UG3 · FY2020 · HL · contact PI
Patient-Oriented Research in Arginine Deficiency Syndromes$179,750
K24 · FY2020 · AT · contact PI
Patient-Oriented Research in Arginine Deficiency Syndromes$180,951
K24 · FY2019 · AT · contact PI
Phase 2 RCT of Arginine Therapy for Pediatric SCD Pain IND #66,943 1/18/13 Active$400,000
R01 · FY2018 · FD · contact PI
Patient-Oriented Research in Arginine Deficiency Syndromes$181,867
K24 · FY2018 · AT · contact PI
Phase 2 RCT of Arginine Therapy for Pediatric SCD Pain IND #66,943 1/18/13 Active$400,000
R01 · FY2017 · FD · contact PI
Arginine therapy for the treatment of pain in children with sickle cell disease$196,755
R34 · FY2017 · HL · contact PI
Phase 2 RCT of Arginine Therapy for Pediatric SCD Pain IND #66,943 1/18/13 Active$400,000
R01 · FY2016 · FD · contact PI
Arginine therapy for the treatment of pain in children with sickle cell disease$197,282
R34 · FY2016 · HL · contact PI
Phase 2 RCT of Arginine Therapy for Pediatric SCD Pain IND #66,943 1/18/13 Active$400,000
R01 · FY2015 · FD · contact PI
Arginine therapy for the treatment of pain in children with sickle cell disease$208,216
R34 · FY2015 · HL · contact PI
Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension$399,170
R01 · FY2011 · FD · contact PI
Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension$399,172
R01 · FY2010 · FD · contact PI
Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension$399,246
R01 · FY2009 · FD · contact PI
THE ROLE OF ARGINASE ACTIVITY AND LIMITED ARGININE BIOAVAILABILITY IN ASTHMA$13,687
M01 · FY2005 · RR
ARGININE/SSD$7,285
M01 · FY2005 · RR
ARGININE VOC TRIAL$1,798
M01 · FY2005 · RR
NITRIC OXIDE AS A MARKER FOR DEGREE OF VASO-OCCLUSION IN SICKLE CELL DISEASE$477
M01 · FY2005 · RR
PNEUMONIA NO$55
M01 · FY2005 · RR
ARGININE THERAPY IN SICKLE CELL DISEASE$129,870
K23 · FY2004 · HL
ARGININE/SSD$12,912
M01 · FY2004 · RR
The role of arginase activity and limited arginine bioavailability in asthma$8,390
M01 · FY2004 · RR
PNEUMONIA NO$575
M01 · FY2004 · RR
NO ASTHMA$396
M01 · FY2004 · RR
ARGININE THERAPY IN SICKLE CELL DISEASE$129,870
K23 · FY2003 · HL
ARGININE THERAPY IN SICKLE CELL DISEASE$129,870
K23 · FY2002 · HL
NITRIC OXIDE AS MARKER FOR DEGREE OF VASO OCCLUSION IN SCD$0
M01 · FY2002 · RR
ARGININE THERAPY IN SICKLE CELL DISEASE: PILOT STUDY$0
M01 · FY2002 · RR
ARGININE THERAPY IN SICKLE CELL DISEASE$129,870
K23 · FY2001 · HL
NITRIC OXIDE AS MARKER FOR DEGREE OF VASO OCCLUSION IN SCD$0
M01 · FY2001 · RR
ARGININE THERAPY IN SICKLE CELL DISEASE: PILOT STUDY$0
M01 · FY2001 · RR
ARGININE THERAPY IN SICKLE CELL DISEASE$127,955
K23 · FY2000 · HL
NITRIC OXIDE AS MARKER FOR DEGREE OF VASO OCCLUSION IN SCD$17,457
M01 · FY2000 · RR
ARGININE THERAPY IN SICKLE CELL DISEASE: PILOT STUDY$17,457
M01 · FY2000 · RR
NITRIC OXIDE AS MARKER FOR DEGREE OF VASO OCCLUSION IN SCD$0
M01 · FY2000 · RR
NITRIC OXIDE AS MARKER FOR DEGREE OF VASO OCCLUSION IN SCD$0
M01 · FY2000 · RR
ARGININE THERAPY IN SICKLE CELL DISEASE: PILOT STUDY$0
M01 · FY2000 · RR
ARGININE THERAPY IN SICKLE CELL DISEASE: PILOT STUDY$0
M01 · FY2000 · RR